Bolt Biotherapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Hello and welcome. My name is Michael Schmidt. I am the Senior Biotech Analyst with Guggenheim Securities. It is my great pleasure to welcome the Bolt Biotherapeutics team. With us today, we have Randy Schatzman, CEO, as well as Edith Perez, Chief Medical Officer. Welcome, and thanks for joining us today.
Thanks. Pleasure to be with you, Michael. Thanks for having us joining.
Questions & Answers
So, we'll jump right into questions as we have done before, Randy. You know, just starting out with the big picture one, I guess, coming out of 2021, heading into 2022, what should investors be watching out for with Biotherapeutics as the pipeline is advancing?
Yes, appreciate that. As you can imagine, 2022 for us is going to be a very busy year, both bringing our lead agent, BDC
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |